Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.65 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.65 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.65 |
| ▸ | CGAS | Q8N884 | 2/20 | 0.65 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.65 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.65 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | PRNP | P04156 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069903 | 0.94 | CHRM2 (0.60) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL1695397 | 0.90 | TMEM97 (0.51) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL5074614 | 0.89 | TMEM97 (0.50) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL5071978 | 0.86 | LMNA (0.46) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL1550687 | 0.84 | CDK1 (0.62) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL1550558 | 0.83 | KDM4E (0.46) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL1695719 | 0.82 | KDM4E (0.46) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL16120062 | 0.82 | CHRM2 (0.52) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL18843869 | 0.80 | HSD17B10 (0.60) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL18843927 | 0.80 | HSD17B10 (0.62) | CHRM2CHRM4CHRM5ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11554176-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-1581167-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RES GROUP LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005016196-A1 | COMPOSITIONS AND METHODS FOR DESTABILIZING LYSOSOMES TO INCREASE ONCOGENIC OR ABERRANT PROTEIN DEGRADATION | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004050842-A2 | ATM KINASE COMPOSITIONS AND METHODS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11554176-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | MTPN, MYOF, TNNC1 | CHRM2 3199/4885CHRM4 3813/4885CHRM5 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.